Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
Capital infusion to accelerate Earendil’s R&D platform
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The protections extend through at least 2035, with the potential for further extensions
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
ShunzymeX leverages a proprietary protease to streamline purification
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
Subscribe To Our Newsletter & Stay Updated
